Interesting. Another $50M deal inside this for the

Quote:

---

Upon payment of the $5,000,000 (Five Million USD) licensing fee, the Joint entity will obtain a right of first refusal for the Ii-Key vaccine technology for oncology, infectious disease and autoimmune diseases for a license fee of $50,000,000 (Fifty Million USD). Generex has agreed that if the Vaccine fails the clinical trial, it will compensate the Joint Entity through one of the following methods:



1. Generex will cooperate with the Joint Entity in the entire Ii-Key platform and will grant the Joint Entity an exclusive license to use the Ii-Key platform in a number of additional areas described in the Agreement for a license fee of $50,000,000 (Fifty Million USD) minus the $5,000,000 (Five Million USD) licensing fee paid upon signing the Agreement.
2. Generex will grant the Joint Entity exclusive use of its technology and related intellectual property in Excellagen (our subsidiary Olaregren’s wound management product) for a license fee of $10,000,000 (Ten Million USD) minus the $5,000,000 (Five Million USD) licensing fee paid upon sign the Agreement.

---